Literature DB >> 15646651

Hb Bristol-Alesha presenting thalassemia-type hyperunstable hemoglobinopathy.

Gen Kano1, Akira Morimoto, Shigeyoshi Hibi, Chika Tokuda, Shinjiro Todo, Tohru Sugimoto, Teruo Harano, Ayako Miyazaki, Akira Shimizu, Shinsaku Imashuku.   

Abstract

Hemoglobin (Hb) Bristol-Alesha is caused by a GTG --> ATG mutation at codon 67 in the Hb beta chain, resulting in abnormal beta globin chains with mutated molecules from normal beta67 valine (Val) to beta67 methionine (Met) or beta67 aspartate (Asp). We describe a Japanese child with this rare hemoglobinopathy and a very unstable Hb molecule phenotype. The diagnosis of hemolytic anemia was made when the patient was 6 months of age. Development of marked splenomegaly necessitated red blood cell transfusions twice a month. After splenectomy when the patient was 4 years of age, laboratory findings of hemolytic anemia became more prominent. Specific abnormal Hb molecules initially were not detected, and the alpha/beta globin synthesis ratio was abnormal at 2.22. After splenectomy, we identified the presence of abnormal beta-globin chains with a beta67Val:beta67Met:beta67Asp molecule ratio of 74:11:15. We speculate that the high fraction of the beta67Met molecule in this patient, compared with that in previously reported cases, caused extreme Hb instability, which resulted in thalassemic hyperunstable hemoglobinopathy and very severe clinical findings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15646651     DOI: 10.1532/ijh97.04048

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  22 in total

Review 1.  Is it dominantly inherited beta thalassaemia or just a beta-chain variant that is highly unstable?

Authors:  S L Thein
Journal:  Br J Haematol       Date:  1999-10       Impact factor: 6.998

2.  [Congenital hemolytic anemia caused by the carriage of hemoglobin Bristol beta 67 Bal-->Asp].

Authors:  E A Aseeva; I N Lutsenko; A V Pivnik; V A Spivak; L S Beliaeva; N M Zhestkova
Journal:  Ter Arkh       Date:  1992       Impact factor: 0.467

3.  [Not Available].

Authors:  H HORLEIN; G WEBER
Journal:  Dtsch Med Wochenschr       Date:  1948-10-15       Impact factor: 0.628

4.  Post-translational modification from methionine to aspartic acid-residue on a variant hemoglobin, Hb Bristol, a proof by ESI-MS-MS.

Authors:  A Miyazaki; T Nakanishi; M Kishikawa; A Shimizu; Y Ohba; A Tanaka; H Sasaki
Journal:  J Mass Spectrom       Date:  1996-11       Impact factor: 1.982

5.  Frequency of abnormal human haemoglobins caused by C----T transitions in CpG dinucleotides.

Authors:  M F Perutz
Journal:  J Mol Biol       Date:  1990-05-20       Impact factor: 5.469

6.  Hb T-Cambodia, a beta chain variant with the mutations of Hb E and Hb D-Punjab, confirmed by DNA analysis.

Authors:  P J Hutt; V F Fairbanks; S N Thibodeau; M M Green; J D Hoyer; S H Block; C Day; R T Jones; R C Barwick
Journal:  Hemoglobin       Date:  1997-05       Impact factor: 0.849

7.  Abnormal processing of beta Knossos RNA.

Authors:  S H Orkin; S E Antonarakis; D Loukopoulos
Journal:  Blood       Date:  1984-07       Impact factor: 22.113

8.  Localization of the site of recombination in formation of the Lepore Boston globin gene.

Authors:  M Baird; H Schreiner; C Driscoll; A Bank
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

9.  A novel silent posttranslational mechanism converts methionine to aspartate in hemoglobin Bristol (beta 67[E11] Val-Met->Asp).

Authors:  D C Rees; J Rochette; C Schofield; B Green; M Morris; N E Parker; H Sasaki; A Tanaka; Y Ohba; J B Clegg
Journal:  Blood       Date:  1996-07-01       Impact factor: 22.113

10.  Hb Alesha or alpha 2 beta (2)67(E11)Val-->Met: a new unstable hemoglobin variant identified through sequencing of amplified DNA.

Authors:  T P Molchanova; D D Pobedimskaya; N S Smetanina; A A Moschan; E G Kazanetz; T H Huisman
Journal:  Hemoglobin       Date:  1993-06       Impact factor: 0.849

View more
  4 in total

1.  A hemoglobin variant associated with neonatal cyanosis and anemia.

Authors:  Moira A Crowley; Todd L Mollan; Osheisa Y Abdulmalik; Andrew D Butler; Emily F Goodwin; Arindam Sarkar; Catherine A Stolle; Andrew J Gow; John S Olson; Mitchell J Weiss
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

2.  Reverse engineering the cooperative machinery of human hemoglobin.

Authors:  Zhong Ren
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

3.  A First Report of Hb Alesha [β67(E11)Val>Met, GTG>ATG] in an Iranian Patient

Authors:  Mohammad Hamid; Ebtesam Zargan Nezhad; Hamid Galehdari; Alihossein Saberi; Gholamreza Shariati; Alireza Sedaghat
Journal:  Iran Biomed J       Date:  2018-10-14

4.  [Hb Alesha of unstable hemoglobinopathy: a case report and literature review].

Authors:  Q Zhang; H C Shi; N Liu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-02-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.